Alejandro Lloret, PhD
Senior Scientist, Antisense Drug Discovery Group at Isis Pharmaceuticals
Location: Carlsbad, CA
United States
Dr. Lloret is involved in the development of antisense-based therapies for neurodegenerative diseases, such as Parkinson’s disease and Huntington’s disease.
Dr. Lloret received his BSc in biology and his PhD in biomedical sciences from the Universidad Nacional Autónoma de México. Prior to joining Isis, he was Research Fellow in Genetics/ Fellow in Neurology at the Center of Human Genetics Research, Massachusetts General Hospital/Harvard Medical School.
His work on genetic modifiers of the age-of-onset in Huntington’s disease was awarded “Poster of Distinction” at the MGH SAC 2005 Research Symposium Poster Session.
Associated Grants
-
Validation of LRRK2 as a Drug Target for Treatment of Parkinson's Disease Using Antisense Technology
2009